← All trials
NCT06043466
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 11, 2023
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Sep 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chongqing Precision Biotech Co., LtdLead sponsor
- Zhejiang UniversityCollaborator
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.